Retention Rate of Acalabrutinib in a Non-interventional Setting
NCT05645172 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 137
Last updated 2025-12-01
Summary
Retention rate of acalabrutinib in a non-interventional setting. This is a prospective, multicentre, non-interventional study to collect real-world data on retention rates of CLL patients prescribed with acalabrutinib in Germany.
Conditions
- Chronic Lymphocytic Leukaemia (CLL)
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-12-12
- Primary Completion
- 2026-10-15
- Completion
- 2026-10-15
Countries
- Germany
Study Locations
More Related Trials
-
National Acalabrutinib Observational Study
NCT05437250 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL
NCT04883749 ·Status: COMPLETED ·Phase: PHASE2
-
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
NCT04008706 ·Status: COMPLETED ·Phase: PHASE3
-
AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database
NCT06548152 ·Status: RECRUITING
-
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT03516617 ·Status: RECRUITING ·Phase: PHASE2
-
Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
NCT04930536 ·Status: COMPLETED ·Phase: PHASE4
-
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL
NCT05950997 ·Status: RECRUITING ·Phase: NA
-
A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting
NCT03720561 ·Status: COMPLETED
-
A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
NCT01034410 ·Status: TERMINATED ·Phase: PHASE2
-
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy
NCT01039376 ·Status: TERMINATED ·Phase: PHASE3
-
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
NCT04716075 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05057494 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
NCT04075292 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
NCT04402138 ·Status: COMPLETED ·Phase: PHASE2
-
Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia
NCT04657094 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy
NCT01051063 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT03836261 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Real-world Study of Acalabrutinib
NCT06767891 ·Status: ENROLLING_BY_INVITATION
-
Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation
NCT04872621 ·Status: COMPLETED
-
Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
NCT05971251 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
NCT06368414 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
NCT05197192 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
NCT02717611 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania
NCT06170671 ·Status: ACTIVE_NOT_RECRUITING